Avacta

Coris BioConcept is a medical device manufacturer specializing in the development, marketing, and sale of rapid diagnostic kits. The company focuses on providing healthcare solutions for the detection of various pathogens, including those responsible for respiratory, gastroenteric, and blood-borne infections. Its product portfolio features COVID test kits, antibiotic resistance detection kits, bacteria detection kits, parasite detection kits, and virus detection kits. By offering a diverse range of diagnostic products, Coris BioConcept aims to enhance the efficiency and accuracy of pathogen detection in healthcare settings.

AffyXell Therapeutics, established in January 2020 as a joint venture between Avacta and Daewoong, focuses on the development of innovative mesenchymal stem cell (MSC) therapies. The company aims to create next-generation cell and gene therapies specifically designed to treat inflammatory and autoimmune diseases, as well as to prevent organ transplant rejection. By harnessing the therapeutic potential of MSCs, AffyXell seeks to provide health professionals with effective treatment options for a range of challenging medical conditions.

Aptuscan is a biotechnology company that specializes in the development of engineered proteins for the pharmaceutical, biotechnology, and diagnostic industries. The company focuses on creating Scannins binding agents, which are designed for the diagnosis and treatment of various diseases. Aptuscan's products serve as valuable resources for identifying binding agents, facilitating the development of therapeutics and diagnostics, as well as providing research reagents.

ReactivLab, Ltd. is a company based in Glasgow, United Kingdom, that specializes in animal diagnostics solutions. Founded in 2007, it focuses on the diagnosis and prognosis of illnesses in animals through the analysis of specific biomarker proteins, particularly acute phase proteins. These proteins serve as diagnostic and prognostic markers that help identify infections, inflammation, neoplasia, and signs of trauma. By providing tools that enable the detection of sub-clinical signs of illness, ReactivLab facilitates early clinical intervention, ultimately improving animal health outcomes. The company operates as a subsidiary of Avacta Group Plc.

Curidium Medica identifies medicines and companion diagnostics for the treatment of central nervous system disorders.

Avacta Animal Health is an veterinary laboratory service provider and diagnostic tester to surgeons, laboratories, research & commercial organizations on animal allergies.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Oxford Medical Diagnostics develops laser-based technology for the analysis of gases. The company focuses on developing a platform for detecting minute quantities of markers in exhaled breath.